Skip to main content

Table 3 Baseline characteristics for all patients

From: Impact of viral multiplex real-time PCR on management of respiratory tract infection: a retrospective cohort study

 

Missing

Total

Viral a

Any virus b

Other c

p-value d

values

(n = 254)

(n = 80)

(n = 91)

(n = 174)

Viral vs. any virus

Viral vs. other

Demographics

 Age, mean years ± SD (range)

 

41.5 ± 26.9 (0–88)

29.0 ± 27.5 (0–83)

29.6 ± 27.4 (0–83)

47.2 ± 24.7 (0–88)

0.89

<0.001

 Female sex, n (%)

 

107 (42.1)

28 (35.0)

37 (40.7)

79 (45.4)

0.45

0.12

 Children, n (%)

 

72 (28.3)

40 (50.0)

45 (49.5)

32 (18.4)

0.94

<0.001

 Outpatients, n (%)

 

23 (9.1)

7 (8.8)

7 (7.7)

16 (9.2)

0.80

0.91

Comorbidities, n (%)

 Asthma

 

14 (5.5)

3 (3.8)

5 (5.5)

11 (6.3)

0.87

0.61

 COPD

 

27 (10.6)

5 (6.3)

7 (7.7)

22 (12.6)

0.71

0.13

 Other chronic lung diseasee

 

39 (15.4)

9 (11.3)

10 (11.0)

30 (17.2)

0.96

0.22

 Solid cancerf

 

26 (10.2)

3 (3.8)

3 (3.3)

23 (13.2)

1.00

0.02

 Haematologic malignancy

 

48 (18.9)

21 (26.3)

24 (26.4)

27 (15.5)

0.99

0.04

 Organ transplantation

 

14 (5.5)

4 (5.0)

4 (4.4)

10 (5.7)

1.00

1.00

 Neutropenia

 

29 (11.4)

17 (21.3)

17 (18.7)

12 (6.9)

0.68

<0.001

 HIV infection

 

6 (2.4)

1 (1.3)

2 (2.2)

5 (2.9)

1.00

0.77

 Diabetes mellitus

 

27 (10.6)

6 (7.5)

7 (7.7)

21 (12.1)

0.96

0.28

 Collagen vascular disease/Vasculitis

 

33 (13.0)

4 (5.0)

5 (5.5)

29 (16.7)

1.00

0.01

 Systemic steroids

 

57 (22.4)

16 (20.0)

20 (22.0)

41 (23.6)

0.75

0.53

 Other Immunosuppressiong

 

24 (9.4)

8 (10.0)

9 (9.9)

16 (9.2)

0.98

0.84

 Chronic renal failure

 

45 (17.7)

11 (13.8)

13 (14.3)

34 (19.5)

0.92

0.26

Clinical findings

 Systolic blood pressure, mmHg, mean ± SD (range)

38

120 ± 25 (59–207)

121 ± 26 (63–207)

119 ± 26 (63–207)

119 ± 24 (59–197)

0.67

0.60

 Heart rate, beats/min, mean ± SD (range)

11

106 ± 31 (51–234)

114 ± 35 (51–186)

114 ± 33 (51–186)

102 ± 28 (56–234)

1.00

0.01

 Respiratory rate, breaths/min, mean ± SD (range)

145

34 ± 18 (10–103)

37 ± 21 (12–103)

37 ± 20 (12–103)

32 ± 15 (10–88)

1.00

0.17

 Body temperature, °C, mean ± SD (range)

23

37.6 ± 1.0 (35.0–42.0)

37.5 ± 1.0 (35.0–39.6)

37.5 ± 1.0 (35.0–39.6)

37.6 ± 1.0 (35.1–42.0)

1.00

0.48

Laboratory findingsh, mean ± SD (range)

 C-reactive protein (maximum), mg/l

15

132 ± 134 (1–999)

111 ± 127 (1–500)

117 ± 132 (1–500)

141 ± 137 (1–999)

0.77

0.11

 White blood cells (maximum), G/l

13

12.8 ± 11.0 (0.0–97.0)

12.4 ± 13.8 (0.2–97.0)

13.1 ± 14.0 (0.2–97.0)

13.1 ± 9.4 (0.0–63.1)

0.75

0.69

 Platelets (minimum), G/l

13

215 ± 134 (4–713)

208 ± 156 (5–674)

204 ± 149 (5–674)

218 ± 123 (4–713)

0.87

0.62

Discharge diagnosis, n (%)

 Bronchitis

 

32 (12.6)

16 (20.0)

16 (17.6)

16 (9.2)

0.69

0.02

 Acute exacerbation of COPD

 

5 (2.0)

1 (1.3)

1 (1.1)

4 (2.3)

1.00

0.99

 Upper respiratory tract infection

 

22 (8.7)

13 (16.3)

14 (15.4)

9 (5.2)

0.88

0.004

 Respiratory tract infection, unspecified

 

11 (4.3)

6 (7.5)

8 (8.8)

5 (2.9)

0.76

0.18

 Community-acquired pneumonia

 

80 (31.5)

27 (33.8)

33 (36.3)

53 (30.5)

0.73

0.60

 Hospital-acquired pneumonia

 

22 (8.7)

5 (6.3)

6 (6.6)

17 (9.8)

0.93

0.36

 Aspiration pneumonia

 

3 (1.2)

1 (1.3)

2 (2.2)

2 (1.1)

1.00

1.00

 Tuberculosis

 

3 (1.2)

0 (0.0)

0 (0.0)

3 (1.7)

n/a

0.64

 Otheri

 

76 (29.9)

11 (13.8)

11 (12.1)

65 (37.4)

0.75

<0.001

  1. °C, degree Celsius, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, n number, SD standard deviation
  2. aCases in which only one or more respiratory viruses were detected
  3. bCases in which one or more respiratory viruses were detected (as single or mixed infection)
  4. cIncludes bacterial etiology, mixed etiology, no pathogen
  5. dFor continuous variables, 2-sample independent t-test was used. For categorical variables, Mantel-Haenszel chi square or Fisher exact test were used
  6. eOther chronic lung diseases, e.g. cystic fibrosis, pulmonary sarcoidosis, pulmonary hypertension
  7. fAll solid tumors including bronchial carcinoma
  8. gPatients with one of the following conditions: primary or secondary antibody deficiency, congenital immunodeficiency, immunosuppressive therapy other than steroids, severe malnutrition with cachexia
  9. hHighest/lowest value within a time period of 3 days before and 3 days after date of rtPCR
  10. iOther infections (n = 24); neoplastic diseases (n = 7); collagen vascular; other rheumatologic or autoimmune (n = 15); sarcoidosis (n = 3); non-infectious non-neoplastic pulmonary diseases (n = 23); cardiovascular diseases (n = 3); gastroesophageal diseases (n = 1)
Back to article page

Pneumonia

ISSN: 2200-6133

Contact us